QQQ   313.23 (-1.62%)
AAPL   123.41 (-1.37%)
MSFT   229.79 (-1.74%)
FB   256.95 (-0.79%)
GOOGL   2,032.23 (-1.56%)
TSLA   680.46 (-0.87%)
AMZN   3,040.12 (-1.76%)
NVDA   519.55 (-3.11%)
BABA   235.54 (+0.48%)
CGC   33.96 (-3.66%)
GE   13.37 (+3.00%)
MU   91.52 (+0.47%)
NIO   42.96 (-0.76%)
AMD   82.60 (-1.82%)
T   28.37 (+0.53%)
F   12.20 (-2.79%)
ACB   10.72 (-2.81%)
DIS   193.99 (+0.03%)
BA   229.24 (+2.73%)
NFLX   527.61 (-3.69%)
PFE   33.61 (+0.30%)
QQQ   313.23 (-1.62%)
AAPL   123.41 (-1.37%)
MSFT   229.79 (-1.74%)
FB   256.95 (-0.79%)
GOOGL   2,032.23 (-1.56%)
TSLA   680.46 (-0.87%)
AMZN   3,040.12 (-1.76%)
NVDA   519.55 (-3.11%)
BABA   235.54 (+0.48%)
CGC   33.96 (-3.66%)
GE   13.37 (+3.00%)
MU   91.52 (+0.47%)
NIO   42.96 (-0.76%)
AMD   82.60 (-1.82%)
T   28.37 (+0.53%)
F   12.20 (-2.79%)
ACB   10.72 (-2.81%)
DIS   193.99 (+0.03%)
BA   229.24 (+2.73%)
NFLX   527.61 (-3.69%)
PFE   33.61 (+0.30%)
QQQ   313.23 (-1.62%)
AAPL   123.41 (-1.37%)
MSFT   229.79 (-1.74%)
FB   256.95 (-0.79%)
GOOGL   2,032.23 (-1.56%)
TSLA   680.46 (-0.87%)
AMZN   3,040.12 (-1.76%)
NVDA   519.55 (-3.11%)
BABA   235.54 (+0.48%)
CGC   33.96 (-3.66%)
GE   13.37 (+3.00%)
MU   91.52 (+0.47%)
NIO   42.96 (-0.76%)
AMD   82.60 (-1.82%)
T   28.37 (+0.53%)
F   12.20 (-2.79%)
ACB   10.72 (-2.81%)
DIS   193.99 (+0.03%)
BA   229.24 (+2.73%)
NFLX   527.61 (-3.69%)
PFE   33.61 (+0.30%)
QQQ   313.23 (-1.62%)
AAPL   123.41 (-1.37%)
MSFT   229.79 (-1.74%)
FB   256.95 (-0.79%)
GOOGL   2,032.23 (-1.56%)
TSLA   680.46 (-0.87%)
AMZN   3,040.12 (-1.76%)
NVDA   519.55 (-3.11%)
BABA   235.54 (+0.48%)
CGC   33.96 (-3.66%)
GE   13.37 (+3.00%)
MU   91.52 (+0.47%)
NIO   42.96 (-0.76%)
AMD   82.60 (-1.82%)
T   28.37 (+0.53%)
F   12.20 (-2.79%)
ACB   10.72 (-2.81%)
DIS   193.99 (+0.03%)
BA   229.24 (+2.73%)
NFLX   527.61 (-3.69%)
PFE   33.61 (+0.30%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 BELLUS Health22nd Century GroupSynairgenBioTimeProMetic Life Sciences
SymbolTSE:BLUNYSEAMERICAN:XXIILON:SNGNYSEAMERICAN:BTXTSE:PLI
Price Information
Current PriceC$4.92$2.94GBX 174$2.31C$13.60
52 Week RangeBuyBuyN/AN/AN/A
MarketRank™
Overall Score0.50.60.40.50.5
Analysis Score0.00.00.00.00.0
Community Score2.42.82.02.62.6
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market CapC$384.64 million$417.97 million£343.85 million$345.68 millionC$315.66 million
BetaN/AN/AN/AN/AN/A
Average Volume328,3173,601,8792,525,922719,4798,002
Sales & Book Value
Annual RevenueC$15,000.00N/A£79,000.00N/AC$39.91 million
Price / Sales25,694.54N/A4,403.17N/A7.94
CashflowC$1.22 per shareN/AGBX 7.27 per shareN/AC$3.45 per share
Price / Cash4.04N/A23.92N/A3.94
Book ValueC$1.88 per shareN/AGBX 7.70 per shareN/AC$6.07 per share
Price / Book2.62N/A0.23N/A2.24
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.54)N/AGBX (5.10)N/AC($63.06)
Trailing P/E RatioN/A0.00N/A0.00N/A
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.34%N/A1.80%N/A37.47%
Current Ratio18.11%N/A6.20%N/A4.06%
Quick Ratio17.57%N/A6.18%N/A3.66%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees17671476487
Shares Outstanding78.34 million138.86 million199.91 million149.64 million23.31 million
Next Earnings Date5/13/2021 (Estimated)3/11/2021 (Confirmed)5/24/2021 (Estimated)N/AN/A
OptionableNot OptionableOptionableNot OptionableOptionableNot Optionable
Comparison Ideas:
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.